Is NCT07226128 recruiting in Indianapolis, IN?

Yes, NCT07226128 is currently recruiting participants at its Indianapolis, IN location. This hiv clinical trial is actively enrolling qualified participants.

How do I join the hiv clinical trial in Indianapolis?

To join this clinical trial in Indianapolis, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Indianapolis clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

HIV Clinical Trial in Indianapolis, IN

About This HIV Study in Indianapolis

The goal of this clinical trial is to learn if depression treatment improves insulin resistance, or how the body uses insulin to lower blood sugar, in people with HIV on HIV treatment. Researchers will compare an internet-based (online) depression treatment program called cognitive behavioral therapy with depression education. In the online group, participants will undergo 9 weekly treatment sessions. The education group will receive learning materials about depression and will be monitored every month. All participants will have 4 study visits over 12 months.

Sponsor: Indiana University

Who Can Participate

Inclusion Criteria

HIV-1 infection, documented as listed clinically in the participant's electronic medical record by any of the following tests: (1) any licensed rapid HIV test, (2) HIV enzyme test kit at any time prior to study entry, (3) at least one detectable HIV-1 antigen, or (4) at least one detectable plasma HIV-1 RNA viral load.

Age ≥ 18 years.

Ongoing receipt of stable antiretroviral therapy of any kind for at least 180 days prior to Screening

Meets the depression definition for this trial:

(1) repeat PHQ-9 ≥10100 result at the Screening Visit (suggesting moderate to severe depressive symptoms), AND

(2) PHQ-9 depressive disorder diagnosis (2 or more of the 9 depressive symptoms, including depressed mood or anhedonia, present in the past 2 weeks), AND

(3) functional impairment (using the tenth PHQ-9 item assessing social/occupational impairment), AND

(4) no evidence that the direct physiological effects of a substance, medication, or medical condition clearly account for the depressive symptoms, AND

(5) no bipolar or psychotic disorders NOTE: The use of antidepressant medications is not

Exclusion Criteria

HbA1c \< 6.5% at Screening

HIV-1 RNA level \< 75 copies/mL at Screening NOTE: There are no CD4 cell count eligibility criteria for this trial. Exclusion Criteria:

Inability to complete written, informed consent

Inability to read and understand English as seen on a computer screen

Diagnosed diabetes mellitus or any previously recorded HbA1c ≥6.5%

History of bipolar disorder or a psychotic disorder, including schizophrenia NOTE: Depressive disorders are not exclusionary.

Incarceration at the time of any study visit

Active suicidality at Entry, as determined by the patient's HIV provider or social worker following a positive response (1, 2, or 3) to PHQ-9 Item #9 and a positive response (yes) to one or more of the three questions (for Question #3, the previous attempt must be within the past 10 years) on the Patient Suicidality Form (see Appendix).

Diagnosed disease or process, besides HIV infection, associated with increased systemic inflammation (including, but not limited to, systemic lupus erythematosus, inflammatory bowel diseases, or other collagen vascular diseases). NOTE: Hepatitis B or C co-infections are NOT exclusionary, but treatment for hepatitis C cannot be provided during study participation

End stage renal disease requiring renal replacement therapy (dialysis, transplantation).

Known or suspected malignancy requiring systemic treatment within 180 days of the Entry Visit. NOTE: Localized treatment for skin cancers is not exclusionary. • Therapy for serious medical illnesses within 14 days prior to the Entry Visit NOTE: Therapy for serious medical illnesses that overlaps with a study visit will result in postponement of that study visit until the course of therapy is completed; postponement outside of the allowed study visit timeframe will result in study discontinuation.

Pregnancy or breastfeeding during the study.

Receipt of investigational agents, cytotoxic chemotherapy, systemic immunosuppressive therapies, systemic glucocorticoids (of any dose), or anabolic steroids at the Entry Visit NOTE: Physiologic testosterone replacement therapy or topical steroids is not exclusionary. Inhaled/nasal steroids are not exclusionary as long as the participant is not also receiving HIV protease inhibitors NOTE: Use of NSAIDS and aspirin are allowed • Active drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Indianapolis?

Yes, this clinical trial (NCT07226128) has an active research site in Indianapolis, IN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

HIV Treatment Options in Indianapolis, IN

If you're searching for hiv treatment options in Indianapolis, IN, this clinical trial (NCT07226128) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Indianapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hiv specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hiv clinical trials near you to find additional studies recruiting in your area.

HIV Clinical Trial in Indianapolis, IN

Expert Care in Indianapolis

IRB Approved

No-Cost Care

Apply for This Indianapolis Location

Why Participate?

Simple Process